; (B) acquiring patents and licensing for each drug of the manufacturer; and (C) costs to purchase or acquire the drug from another company, if applicable. (4) The percentage of total expenditures of the manufacturer on research and development for such drug that was derived from Federal funds. (5) The total expenditures of the manufacturer on research and development for such drug. (6) The total revenue and net profit generated from the applicable drug for each calendar year since drug approval. (7) The total costs associated with marketing and advertising for the applicable drug. (8) Additional information specific to the manufacturer of the applicable drug, such as— (A) the total revenue and net profit of the manufacturer for the period of such increase, as determined by the Secretary; (B) metrics used to determine executive compensation; (C) any additional information related to drug pricing decisions of the manufacturer, such as total expenditures on— (i) drug research and development